Publications

5808 Results

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Authors
A Hay;S Assouline;R Walter;RF Little;A Moseley;G Sperling;A Im;J Foran;J Radich;M Fang;HP Erba;L Michaelis
Journal / Conference
Blood (2019) 134 (Supplement_1): 3905; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
S1612

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Authors
A Advani;A Moseley;M Liedtke;M O'Donnell;I Aldoss;M Mims;K O'Dwyer;M Othus;HP Erba
Journal / Conference
Blood (2019) 134 (Supplement_1): 227; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
S1312

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Authors
E Pogosova-Agadjanyan;A Moseley;F Appelbaum;T Chauncey;I-M Chen;H Erba;J Godwin;I Jenkins;M Fang;M Huynh;K Kopecky;A List;J Naru;J Radich;E Stevens;B Willborg;C Willman;B Wood;Q Zhang;S Meshinchi;D Stirewalt
Journal / Conference
Blood (2019) 134 (Supplement_1): 2691; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
S0106, S0112, SWOG-9031, SWOG-9333

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Authors
T Shanafelt;XV Wang;N Kay;S O'Brien;J Barrientos;C Hanson;HP Erba;RM Stone;M Litzow;M Tallman
Journal / Conference
Blood (2018) 132 (Supplement 1): LBA-4; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E1912

Combined Treatment with Lenalidomide and Epoetin Alfa leads to Durable Responses in patients with Epo-refractory, Lower Risk Non-deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Authors
A List;X Sun;A Verma;JM Bennett;K McGraw;L Nardelli;J Maciejewski;J Altman;P Cheema;D Claxton;R Komrokji;S Luger;RJ Mattison;T Wassenaar;A Artz;CA Schiffer;M Tallman
Journal / Conference
Blood (2019) 134 (Supplement_1): 842 (American Society of Hematology (Dec 7-10, 2019, Orlando, FL)), oral, abst. 637
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E2905

"Many Views on Value" of National Cancer Institute-Sponsored Randomized Trials

Authors
V Nghiem;R Vaidya;D Hershman;M Leblanc;S Ramsey;CD Blanke;J Unger
Journal / Conference
Society for Medical Decision Making Annual Meeting (October 20-23, 2019, Portland, OR), poster
Year
2019
Research Committee(s)
Cancer Care Delivery

Reproducible Findings in Systematic Reviews and Meta-analyses in Oncology: Verify, Then Trust [editorial]

Authors
J Unger
Journal / Conference
JAMA Oncology Sep 5. doi: 10.1001/jamaoncol.2019.2664 [Epub ahead of print]
Year
2019
Research Committee(s)
Cancer Care Delivery
PMID
PMID31486827

Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum

Authors
L Nappi;M Thi;A Lum;D Huntsman;B Eigl;C Martin;B O'Neil;B Maughan;K Chi;A So;P Black;M Gleave;A Wyatt;J Lavoie;D Khalaf;R Bell;S Daneshmand;R Hamilton;R Leao;C Nichols;C Kollmannsberger
Journal / Conference
Journal of Clinical Oncology, Nov 20;37 (33), 3090-3098
Year
2019
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID31553692
PMC
PMC7351323
Study Number(s)
S1823

Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor

Authors
L Nappi;M Thi;A Lum;D Huntsman;B Eigl;K Chi;C Martin;B O'Neil;B Maughan;A So;P Black;M Gleave;A Wyatt;J Lavoie;D Khalaf;S Daneshmand;R Hamilton;R Leao;C Nichols;C Kollmannsberger
Journal / Conference
J Clin Oncol 37, 2019 (suppl 7S; abstr 526), poster; ASCO GU Cancers Symposium
Year
2019
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S1823

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Authors
E Stadtmauer;M Pasquini;B Blackwell;P Hari;A Bashey;S Devine;Y Efebera;S Ganguly;C Gasparetto;N Geller;M Horowitz;J Koreth;K Knust;H Landau;C Brunstein;P McCarthy;C Nelson;M Qasilbash;N Shah;D Vesole;R Vij;D Vogl;S Giralt;G Somlo;A Krishnan
Journal / Conference
Journal of Clinical Oncology Mar 1;37(7):589-597
Year
2019
Research Committee(s)
Myeloma
PMID
PMID30653422
PMC
PMC6553842
Study Number(s)
CTSU/CTN0702